Delineation of Target Volume of Stereotactic Radiotherapy for Spinal Tumors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06587022

Acronym

ST-SBRT

Enrollment

500

Registered

2024-09-19

Start date

2017-01-01

Completion date

2027-12-30

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Tumor

Brief summary

The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors.

Detailed description

The purpose of this study was to compare efficacy and side effects of two target delineation methods for stereotactic radiotherapy of metastatic spinal tumors. This is a bidirectional cohort study planned to enroll approximately 500 patients with metastatic spinal tumors. Patients are divided into two groups according to the target delineation method. Group 1：The target bolume only includes local tumor. Group 2：The target bolume includes local tumor and adjacent vertebral area.

Interventions

RADIATIONTarget volume delineation

Group 1(small target delineation)：The target bolume only includes local tumor. Group 2(small target delineation)：The target bolume includes local tumor and adjacent vertebral area.

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Patients with spinal metastases or primary tumors receiving stereotactic radiotherapy; * Patients with sufficent pre-treatment imaging data * Patients who can cooperate with imaging review and follow-up after radiotherapy.

Exclusion criteria

* Patients with an expected survival of less than 3 months; * Patients with second-course radiotherapy; * Patients with physical conditions that cannot tolerate stereotactic radiotherapy; * Patients with extensive spinal metastasis and no local therapeutic value

Design outcomes

Primary

Measure	Time frame	Description
Disease Control Rate（DCR）	2 years	Disease Control Rate（DCR），including complete response（CR），partial response(PR) and stable disease(SD ).
Pain relief rate	3 months	VAS Score(Visual Analog Scale Score) decreased after treatment

Secondary

Measure	Time frame	Description
Incidence of side effects	2 years	radiation myelitis,radiation esophagitis, etc.

Countries

China

Contacts

Primary ContactHongqing Zhuang, Doctor

hongqingzhuang@163.com13051776232

Backup ContactYuxia Wang

lily31415926@126.com15001292991

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026